>>Signaling Pathways>> PROTAC>>1-N-Boc-3-hydroxyazetidine

1-N-Boc-3-hydroxyazetidine

Catalog No.GC64156

1-N-Boc-3-하이드록시아제티딘은 항체-약물 접합체(ADC) 합성에 사용되는 절단 불가능한 ADC 링커입니다. 1-N-Boc-3-hydroxyazetidine은 PROTAC 합성에 사용할 수 있는 알킬 사슬 기반 PROTAC 링커이기도 합니다.

Products are for research use only. Not for human use. We do not sell to patients.

1-N-Boc-3-hydroxyazetidine Chemical Structure

Cas No.: 141699-55-0

Size 가격 재고 수량
500 mg
US$15.00
재고 있음
1 g
US$18.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

1-N-Boc-3-hydroxyazetidine is a non-cleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs). 1-N-Boc-3-hydroxyazetidine is also a alkyl chain-based PROTAC linker that can be used in the synthesis of PROTACs

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker[1].PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[2].

[1]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16(5):315-337.
[2]. Nalawansha DA, et al. PROTACs: An Emerging Therapeutic Modality in Precision Medicine. Cell Chem Biol. 2020;27(8):998-985.

리뷰

Review for 1-N-Boc-3-hydroxyazetidine

Average Rating: 5 ★★★★★ (Based on Reviews and 31 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for 1-N-Boc-3-hydroxyazetidine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.